An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Key Inclusion Criteria for Patients with nAMD: 1. Any patient aged at least 50 years at the time of enrollment 2. Diagnosis of nAMD (per physician) 3. Previously treated patient cohort, patients that had treatment with any ocular intervention for nAMD in the study eye at any time before starting aflibercept 8 mg, as defined in the protocol 4. For treatment-naïve patient cohort, patients never receiving previous treatment in the study eye for nAMD, as defined in the protocol 5. Initiating treatment with aflibercept 8 mg for nAMD Key Inclusion Criteria for Patients with DME: 1. Any patient aged at least 18 years at the time of enrollment 2. Macular edema associated with DME (per physician) 3. Diagnosis of diabetes mellitus type 1 or type 2 4. For previously treated patient cohort, treatment with another intravitreal (IVT) anti-VEGF agent(s) or IVT steroids, or surgery/laser for DME in the study eye at any time before starting aflibercept 8 mg, as described in the protocol 5. For treatment-naïve patient cohort, patients never previously treated with IVT agents or surgery/laser in the study eye for DME 6. Initiating treatment with aflibercept 8 mg for DME Key Exclusion Criteria for Patients with nAMD 1. Macular edema/hemorrhage/choroidal neovascularization due to any other cause besides nAMD 2. Any systemic or ocular condition that would prevent any improvement of VA in the study eye (eg, permanent visual impairment or blindness from any cause) 3. Any patients that have been treated with photodynamic therapy 4. Treatment with aflibercept 8 mg prior to baseline Key Exclusion Criteria for Patients with DME: 1. Macular edema due to any other cause besides DME 2. Any systemic or ocular condition that would prevent any improvement of visual acuity in the study eye (eg, permanent visual impairment or blindness from any cause) 3. Treatment with aflibercept 8 mg prior to baseline NOTE: Other Protocol-Defined Inclusion / Exclusion Criteria Apply